In the Journals

Oral prostate cancer therapies increase mortality risk for men with cardiovascular conditions

Grace Lu-Yao, PhD
Grace Lu-Yao

Abiraterone acetate and enzalutamide appeared to increase the risk for death among older men with advanced prostate cancer and pre-existing cardiovascular conditions, according to results of a population-based retrospective study published in European Urology.

“Most cancer therapies have side effects. It is important to evaluate whether the benefits of the drug outweigh its risks,” Grace Lu-Yao, PhD, MPH, professor and vice chair of medical oncology at Thomas Jefferson University and associate director of population science at Sidney Kimmel Cancer Center, told HemOnc Today. “For patients with a high baseline risk for [cardiovascular disease], the risk of an adverse [cardiovascular] event might outweigh the benefits of slowing down cancer progression. It depends on the life expectancy of the patients and the aggressiveness of prostate cancer.”

Clinical trials involving abiraterone acetate (Zytiga, Janssen Oncology) or enzalutamide (Xtandi; Astellas, Pfizer) typically exclude men aged 65 years or older with advanced prostate cancer and significant comorbidities, such as cardiovascular disease (CVD) or uncontrolled hypertension. As a result, limited data exist on the effects of the drugs on these men, researchers noted.

In this retrospective, population-based study, Lu-Yao and colleagues used the SEER database to analyze 3,876 older men with advanced prostate cancer treated with abiraterone acetate (n = 2,845) or enzalutamide (n = 1,031). Two-thirds of the men (67%) had at least one pre-existing CVD condition.

All-cause mortality by 6 months served as the primary endpoint. Researchers analyzed this endpoint using modified Poisson regression modeling of relative risk adjusted for confounders and comorbidities. Inpatient hospitalization 6 months before and 6 months after initiation of abiraterone acetate or enzalutamide served as secondary endpoints.

Results showed that one or two pre-existing CVD conditions appeared associated with a 16% higher risk for 6-month mortality (RR = 1.16; 95% CI, 1-1.36) compared with no pre-existing CVD conditions. Men with three or more pre-existing cardiovascular disease conditions had a 56% increased risk for 6-month mortality (RR = 1.56; 95% CI, 1.29-1.88).

Researchers stratified men by chemotherapy status for multivariable analysis.

Based on crude incidence rate ratios, abiraterone acetate appeared associated with higher hospitalization rates regardless of pre-existing CVD conditions among men who did not receive chemotherapy.

Researchers observed no significant differences in hospitalization rates between the drugs among patients who had received chemotherapy. However, post-chemotherapy patients with one or two CVD conditions had a 43% higher hospitalization rate compared with patients who did not have a CVD condition (incidence rate ratio [IRR] = 1.43; 95% CI, 1.15-1.78).

Among men who did not receive chemotherapy and had three or more CVD conditions, those treated with enzalutamide vs. abiraterone acetate had a 41% lower hospitalization rate (IRR = 0.59; 95% CI, 0.44-0.79).

Treatment efficacy could not be determined because of the study’s retrospective nature, which served as its primary limitation.

“I would not recommend against prescribing these drugs to patients with cardiovascular disease conditions at this time,” Lu-Yao said. “For patients with pre-existing CVD conditions, I recommend that these patients be managed by the care team with a cardiologist, who can monitor the CVD risk and take necessary steps when needed.” – by John DeRosier

For more information:

Grace Lu-Yao, PhD, MPH, can be reached at Thomas Jefferson University, BLSB 812, 233 S. 10th St., Philadelphia, PA, 19107; email: grace.luyao@jefferson.edu.

Disclosures: The authors report no relevant financial disclosures.

 

Grace Lu-Yao, PhD
Grace Lu-Yao

Abiraterone acetate and enzalutamide appeared to increase the risk for death among older men with advanced prostate cancer and pre-existing cardiovascular conditions, according to results of a population-based retrospective study published in European Urology.

“Most cancer therapies have side effects. It is important to evaluate whether the benefits of the drug outweigh its risks,” Grace Lu-Yao, PhD, MPH, professor and vice chair of medical oncology at Thomas Jefferson University and associate director of population science at Sidney Kimmel Cancer Center, told HemOnc Today. “For patients with a high baseline risk for [cardiovascular disease], the risk of an adverse [cardiovascular] event might outweigh the benefits of slowing down cancer progression. It depends on the life expectancy of the patients and the aggressiveness of prostate cancer.”

Clinical trials involving abiraterone acetate (Zytiga, Janssen Oncology) or enzalutamide (Xtandi; Astellas, Pfizer) typically exclude men aged 65 years or older with advanced prostate cancer and significant comorbidities, such as cardiovascular disease (CVD) or uncontrolled hypertension. As a result, limited data exist on the effects of the drugs on these men, researchers noted.

In this retrospective, population-based study, Lu-Yao and colleagues used the SEER database to analyze 3,876 older men with advanced prostate cancer treated with abiraterone acetate (n = 2,845) or enzalutamide (n = 1,031). Two-thirds of the men (67%) had at least one pre-existing CVD condition.

All-cause mortality by 6 months served as the primary endpoint. Researchers analyzed this endpoint using modified Poisson regression modeling of relative risk adjusted for confounders and comorbidities. Inpatient hospitalization 6 months before and 6 months after initiation of abiraterone acetate or enzalutamide served as secondary endpoints.

Results showed that one or two pre-existing CVD conditions appeared associated with a 16% higher risk for 6-month mortality (RR = 1.16; 95% CI, 1-1.36) compared with no pre-existing CVD conditions. Men with three or more pre-existing cardiovascular disease conditions had a 56% increased risk for 6-month mortality (RR = 1.56; 95% CI, 1.29-1.88).

Researchers stratified men by chemotherapy status for multivariable analysis.

Based on crude incidence rate ratios, abiraterone acetate appeared associated with higher hospitalization rates regardless of pre-existing CVD conditions among men who did not receive chemotherapy.

Researchers observed no significant differences in hospitalization rates between the drugs among patients who had received chemotherapy. However, post-chemotherapy patients with one or two CVD conditions had a 43% higher hospitalization rate compared with patients who did not have a CVD condition (incidence rate ratio [IRR] = 1.43; 95% CI, 1.15-1.78).

PAGE BREAK

Among men who did not receive chemotherapy and had three or more CVD conditions, those treated with enzalutamide vs. abiraterone acetate had a 41% lower hospitalization rate (IRR = 0.59; 95% CI, 0.44-0.79).

Treatment efficacy could not be determined because of the study’s retrospective nature, which served as its primary limitation.

“I would not recommend against prescribing these drugs to patients with cardiovascular disease conditions at this time,” Lu-Yao said. “For patients with pre-existing CVD conditions, I recommend that these patients be managed by the care team with a cardiologist, who can monitor the CVD risk and take necessary steps when needed.” – by John DeRosier

For more information:

Grace Lu-Yao, PhD, MPH, can be reached at Thomas Jefferson University, BLSB 812, 233 S. 10th St., Philadelphia, PA, 19107; email: grace.luyao@jefferson.edu.

Disclosures: The authors report no relevant financial disclosures.